Morgan Stanley
STLN

Morgan Stanley’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Morgan Stanley’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$528K Sell
171,940
-50,113
-23% -$154K ﹤0.01% 5457
2025
Q4 		$791K Buy
222,053
+131,037
+144% +$486K ﹤0.01% 5302
2025
Q3 		$318K Sell
91,016
-84,357
-48% -$289K ﹤0.01% 5702
2025
Q2 		$360K Buy
175,373
+144,885
+475% +$362K ﹤0.01% 5616
2025
Q1 		$34.8K Buy
30,488
+96
+0.3% +$74 ﹤0.01% 6387
2024
Q4 		$9.39K Hold
30,392
– – ﹤0.01% 6826
2024
Q3 		$9.94K Buy
30,392
+1,052
+4% +$436 ﹤0.01% 6722
2024
Q2 		$13.5K Sell
29,340
-41,214
-58% -$35.2K ﹤0.01% 6575
2024
Q1 		$111K Buy
70,554
+22,586
+47% +$42.9K ﹤0.01% 5944
2023
Q4 		$97.9K Buy
47,968
+42,506
+778% +$73.7K ﹤0.01% 6172
2023
Q3 		$7.65K Sell
5,462
-4,038
-43% -$4.18K ﹤0.01% 6807
2023
Q2 		$5.23K Sell
9,500
-8,506
-47% -$4.5K ﹤0.01% 6977
2023
Q1 		$12.2K Sell
18,006
-408
-2% -$520 ﹤0.01% 6818
2022
Q4 		$30.4K Buy
18,414
+16,989
+1,192% +$47.7K ﹤0.01% 6510
2022
Q3 		$6K Buy
1,425
+222
+18% +$1.3K ﹤0.01% 7219
2022
Q2 		$6K Sell
1,203
-3,272
-73% -$23.8K ﹤0.01% 7370
2022
Q1 		$33K Buy
4,475
+3,543
+380% +$23.9K ﹤0.01% 6905
2021
Q4 		$9K Buy
+932
New +$8.28K ﹤0.01% 7512
2021
Q3 		– Sell
-20,098
Closed -$200K – 8024
2021
Q2 		$200K Sell
20,098
-4,984
-20% -$50.2K ﹤0.01% 6017
2021
Q1 		$250K Buy
25,082
+24,062
+2,359% +$256K ﹤0.01% 5532
2020
Q4 		$11K Buy
1,020
+945
+1,260% +$9.73K ﹤0.01% 6609
2020
Q3 		$1K Buy
+75
New +$779 ﹤0.01% 6673

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley's STLN Position: Q1 2026 in Review

Morgan Stanley reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 23% in Q1 2026, selling an estimated $154K and leaving 171,940 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #5457.

Morgan Stanley first reported a position in STLN in Q3 2020 and has held it in 22 quarters since. The position peaked at $791K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Morgan Stanley held 171,940 shares of Starling Oncology Institute, Inc. Common Stock worth $528K as of Q1 2026.
  • Morgan Stanley sold 50,113 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $154K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5457 holding.
  • Morgan Stanley first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2020 and has held it in 22 quarters since.
  • Morgan Stanley's Starling Oncology Institute, Inc. Common Stock position peaked at $791K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.